5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Viyash Scientific Ltd.

•
viyash.comBSE: 512529NSE: VIYASH
Market Cap₹ 11,332 Cr.
Current Price
High / Low₹ 298 / 178
Stock P/E66.2
Book Value₹ 64
Price to Book2.96
Dividend Yield0.00 %
ROCE13.1 %
ROE9.1 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2017 • Pharmaceuticals: 99.3% • Analytical Services: 0.7%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Promoters have been increasing their shareholding - up 8.5pp over 2 years
  • Latest quarter profit grew 351.3% YoY, showing strong momentum
  • Operating margins have improved to 19.1% from 1.3%
  • Company has delivered good sales growth of 20.2% CAGR over last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.31x)

CONS

  • Company has a low return on equity of 1.8% over last 3 years
  • Company has a low return on capital employed of 5.8%
  • Receivables are growing faster than sales - a possible quality concern
  • Equity base is being diluted - shares outstanding up 75.1%
  • Working capital days have increased from 93 to 140 days
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.VIYASH257.2566.2111332.390.00792.904412.819463.602043.9013.1018.85
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3333463293613903697747724414248589209,464
3413313073293483306746593893686837368,423
Operating Profit-8152232423910011352561761841,041
OPM %-2.47%4.37%6.76%8.93%10.75%10.61%12.89%14.62%11.82%13.13%20.46%20.03%11.00%
-23107-1304-6430-271683
Interest101313121614212114141715125
Depreciation141515161617586515155960618
Profit before Tax-56-31312824-372627731251,124
Tax %37.72%-122.65%-616.78%51.89%24.50%19.75%-71.32%12.22%31.15%27.84%33.60%47.00%29.46%
Net Profit0000966510418204966793
-1.40-0.340.33-0.040.260.111.04-0.610.570.590.891.201.51

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
6848481,0391,1791,3621,4131,4211,3703,0073,42011,666
6417659141,0091,1521,3031,4091,3082,6232,76810,209
Operating Profit438312517021010912613846531,457
OPM %6.28%9.79%12.02%14.44%15.42%7.74%0.84%4.48%12.77%19.08%12.49%
1115910211-58-6-46-172
Interest28333336241636488669170
Depreciation4041425151525662239234752
Profit before Tax-1424599413753-138-55133491,350
Tax %3.66%56.91%3.41%12.79%23.55%15.43%11.39%45.81%-19.62%35.63%31.28%
Net Profit-1410578210445-122-3016225927
EPS-0.5717.291.992.853.851.63-4.88-1.440.934.06—
Dividend Payout %0.00%1.16%10.15%0.00%13.01%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
19%
5 Years:
20%
3 Years:
34%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
13%
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
—

RETURN ON EQUITY

10 Years:
3%
5 Years:
-1%
3 Years:
2%
Last Year:
9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2021

Sep 8

₹ 0.25

Rs.0.5000 per share(25%)Final Dividend

2017

Nov 20

₹ 0.10

Rs.0.2000 per share(10%)Interim Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital49494950505050505087
Minority Interest1737404549485056133204
9125816386236705955935292,2022,618
470403364411270356370418719616
Trade Payables203160209220227258244251489597
252113100114178179177227426423
Total Liabilities1,9041,3431,4021,4631,4431,4871,4841,5314,0204,545
6844764985775365646055922,1032,103
Capital Work in Progress213171129951114369
42823918017183380400
161159200219264348346346682803
00000003368061,045
Cash & Bank4742727656594270157270
582413434409475468439173228255
Total Assets1,9041,3431,4021,4631,4431,4871,4841,5314,0204,545

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
254115127159573131345323
Cash from Investing-1167-68-7210-96-65-6-447-84
Cash from Financing147-57-20-43-1396732-187-123
24-5280-142-1623-15115

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
52.7852.7652.6152.6152.6152.3361.4161.3161.31
5.696.456.106.056.155.903.162.944.50
8.069.9912.0012.8112.9812.917.367.983.76
Government0.000.000.000.000.000.000.000.000.00
33.4630.8029.2928.5328.2628.8528.0627.7630.43

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
General Updates

2026-09-08 - Update on proposed acquisition of BioForLife Italia S.r.l

2026-09-04
General Updates

2026-09-04 - Viyash Scientific Limited has informed the Exchange about ESOP Allotment

2026-08-16
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-16 - Viyash Scientific Limited has informed the Exchange about Transcript

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Viyash Scientific Limited has informed the Exchange about Link of Earning call Recording

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Viyash Scientific Limited has informed the Exchange about Copy of Newspaper Publication for Q1 FY 27 Financial Results.

2026-08-12
Investor Presentation

2026-08-12 - Viyash Scientific Limited has informed the Exchange about Investor Presentation

2026-08-11
Shareholders meeting

2026-08-11 - Viyash Scientific Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 11, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-11
Shareholders meeting

2026-08-11 - Viyash Scientific Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026

2026-08-11
Press Release

2026-08-11 - Viyash Scientific Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Press Release for Q1 FY 2026-27".

News

Recent coverage and analyst commentary for VIYASH

Loading news…

🤖

AI Stock Analyst

Viyash Scientific Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login